T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

Hammarström, 1999, The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues, Semin Cancer Biol, 9, 67, 10.1006/scbi.1998.0119

Hance, 2005, Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines, Mutat Res, 576, 132, 10.1016/j.mrfmmm.2004.10.014

Foon, 1999, Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen, J Clin Oncol, 17, 2885, 10.1200/JCO.1999.17.9.2889

Hörig, 2000, Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 costimulatory molecule, Cancer Immunol Immunother, 49, 504, 10.1007/s002620000146

Marshall, 2000, Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses, J Clin Oncol, 18, 3964, 10.1200/JCO.2000.18.23.3964

Smith, 2002, Immunotherapy of colorectal cancer, Br Med Bull, 64, 181, 10.1093/bmb/64.1.181

Parkhurst, 2009, Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells, Clin Cancer Res, 15, 169, 10.1158/1078-0432.CCR-08-1638

Robbins, 2008, Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions, J Immunol, 180, 6116, 10.4049/jimmunol.180.9.6116

Johnson, 2009, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, 114, 535, 10.1182/blood-2009-03-211714

Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003

Dudley, 2008, Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens, J Clin Oncol, 26, 5233, 10.1200/JCO.2008.16.5449

Warren, 2010, Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens, Blood, 115, 3869, 10.1182/blood-2009-10-248997

Klebanoff, 2006, CD8+ T-cell memory in tumor immunology and immunotherapy, Immunol Rev, 211, 214, 10.1111/j.0105-2896.2006.00391.x

Burns, 2009, Lack of specific γ-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation, Blood, 114, 2888, 10.1182/blood-2009-01-199216

Dudley, 2002, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, 298, 850, 10.1126/science.1076514

Robbins, 2004, Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy, J Immunol, 173, 7125, 10.4049/jimmunol.173.12.7125

Rosenberg, 2009, Adoptive cell therapy for the treatment of patients with metastatic melanoma, Curr Opin Immunol, 21, 233, 10.1016/j.coi.2009.03.002

Brenner, 2010, Adoptive T cell therapy of cancer, Curr Opin Immunol, 22, 251, 10.1016/j.coi.2010.01.020

June, 2009, Engineering lymphocyte subsets: tools, trials and tribulations, Nat Rev Immunol, 9, 704, 10.1038/nri2635

Shibata, 2009, A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies, Clin Cancer Res, 15, 2935, 10.1158/1078-0432.CCR-08-2213

Zeh, 2009, A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer, Ann Surg Oncol, 16, 385, 10.1245/s10434-008-0179-5

Blesa, 2010, Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient, Anticancer Drugs, 21, S23, 10.1097/01.cad.0000361533.36428.0b

van Loenen, 2010, Mixed T cell receptor dimers harbor potentially harmful neoreactivity, Proc Natl Acad Sci USA, 107, 10972, 10.1073/pnas.1005802107

Bendle, 2010, Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy, Nat Med, 16, 565, 10.1038/nm.2128

Cohen, 2006, Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability, Cancer Res, 66, 8878, 10.1158/0008-5472.CAN-06-1450

Voss, 2006, Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression, Immunol Res, 34, 67, 10.1385/IR:34:1:67

Stanislawski, 2001, Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer, Nat Immunol, 2, 962, 10.1038/ni1001-962

Rosenberg, 2010, Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells, Mol Ther, 18, 1744, 10.1038/mt.2010.195

Whiteside, 2008, The tumor microenvironment and its role in promoting tumor growth, Oncogene, 27, 5904, 10.1038/onc.2008.271

Paulos, 2007, Toll-like receptors in tumor immunotherapy, Clin Cancer Res, 13, 5280, 10.1158/1078-0432.CCR-07-1378

Bos, 2008, Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen, Cancer Res, 68, 8446, 10.1158/0008-5472.CAN-08-1864

Zhao, 2009, A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity, J Immunol, 183, 5563, 10.4049/jimmunol.0900447